These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 2433088

  • 1. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    St-Arnaud R, Lachance R, Dupont A, Labrie F.
    Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
    [Abstract] [Full Text] [Related]

  • 2. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R, Lachance R, Dupont A, Labrie F.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [Abstract] [Full Text] [Related]

  • 3. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A, Labrie F, Dupont A, Brochu M, Cusan L.
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 Oct; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 5. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH, Goldstein M, Kourides IA, Comite F, Bardin CW, Krieger DT.
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [Abstract] [Full Text] [Related]

  • 6. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
    St-Arnaud R, Lachance R, Kelly SJ, Belanger A, Dupont A, Labrie F.
    Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
    [Abstract] [Full Text] [Related]

  • 7. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelber H, Leiter C, Farkas A, Spitz IM.
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [Abstract] [Full Text] [Related]

  • 8. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983 Mar; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 9. Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture.
    Hubert JF, Simard J, Gagné B, Barden N, Labrie F.
    Mol Endocrinol; 1988 Jun; 2(6):521-7. PubMed ID: 2458526
    [Abstract] [Full Text] [Related]

  • 10. Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland.
    Simard J, Labrie C, Hubert JF, Labrie F.
    Mol Endocrinol; 1988 Sep; 2(9):775-84. PubMed ID: 2459604
    [Abstract] [Full Text] [Related]

  • 11. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A.
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [Abstract] [Full Text] [Related]

  • 12. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T, Nishizawa K, Mitsumori K.
    Scand J Urol Nephrol; 2006 Mar; 40(3):198-203. PubMed ID: 16809259
    [Abstract] [Full Text] [Related]

  • 13. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P.
    Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
    [Abstract] [Full Text] [Related]

  • 14. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 15. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
    Lacoste D, Dubé D, Bélanger A, Labrie F.
    Mol Cell Endocrinol; 1989 Dec 01; 67(2-3):131-8. PubMed ID: 2693158
    [Abstract] [Full Text] [Related]

  • 16. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J.
    Urol Int; 2006 Dec 01; 77(2):135-8. PubMed ID: 16888418
    [Abstract] [Full Text] [Related]

  • 17. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R, Pahalajani G, Agarwal A, Zippe C.
    Asian J Androl; 2007 Mar 01; 9(2):253-8. PubMed ID: 17334592
    [Abstract] [Full Text] [Related]

  • 18. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G.
    J Steroid Biochem; 1986 Nov 01; 25(5B):877-83. PubMed ID: 3100871
    [Abstract] [Full Text] [Related]

  • 19. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
    Doelle G, Linde R, Alexander N, Kirchner F, Vale W, Rivier J, Rabin D.
    Int J Fertil; 1982 Nov 01; 27(4):234-7. PubMed ID: 6131043
    [Abstract] [Full Text] [Related]

  • 20. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.